Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study-Reference-Cited by-同舟云学术

Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study

Published:2016-08-09 Issue:1 Volume:31 Page:89-95
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Cai L.¹,Gu J.²,Zheng J.³,Zheng M.⁴,Wang G.⁵,Xi L.-Y.⁶,Hao F.⁷,Liu X.-M.⁸,Sun Q.-N.⁹,Wang Y.¹⁰,Lai W.¹¹,Fang H.¹²,Tu Y.-T.¹³,Sun Q.¹⁴,Chen J.¹⁵,Gao X.-H.¹⁶,Gu Y.¹⁷,Teixeira H.D.¹⁷,Zhang J.-Z.¹,Okun M.M.¹⁸

Affiliation:

1. Peking University People's Hospital; Beijing China

2. Shanghai Changhai Hospital; Shanghai China

3. Ruijin Hospital of Shanghai Jiao Tong University School of Medicine; Shanghai China

4. Second Affiliated Hospital Zhejiang University College of Medicine; Hangzhou China

5. The first Affiliated Hospital of Fourth Military Medical University; PLA (Xijing Hospital); Xi'an China

6. Sun Yat-sen Memorial Hospital; Sun Yat-sen University; Guangzhou China

7. The First Affiliated Hospital of Third Military Medical University; PLA (Southwest Hospital); Chongqing China

8. First Affiliated Hospital of Dalian Medical University; Dalian China

9. Peking Union Medical College Hospital; Beijing China

10. Peking University First Hospital; Beijing China

11. The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China

12. The First Affiliated Hospital of College of Medicine; Zhejiang University; Hangzhou China

13. Union Hospital Tongji Medical College Huazhong University of Science and Technology; Wuhan China

14. Qilu Hospital of Shandong University; Jinan China

15. Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital; Chengdu China

16. The First Hospital of China Medical University; Shenyang China

17. AbbVie Inc.; North Chicago IL USA

18. Fort HealthCare; Fort Atkinson WI USA

Funder

AbbVie

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.13746/fullpdf

Reference19 articles.

1. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011;Armstrong;Dermatology,2012

2. Psoriasis: comorbidities and associations;Farley;G Ital Dermatol Venereol,2011

3. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening;Kimball;J Am Acad Dermatol,2008

4. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study;Yeung;JAMA Dermatol,2013

5. Psoriasis;Lebwohl;Lancet,2003

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis;JEADV Clinical Practice;2024-01-05

2. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15

3. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis;Dermatology and Therapy;2023-10-06

4. Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis;Journal of Dermatological Treatment;2023-08-22

5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12